Half Year Results
Filed with ASX · · 4 pages · English
Resonance Health Limited (ASX: RHT) (“Resonance” or “Company”) is pleased to release its Appendix 4D and Half-Year Financial Report for the six-months ended 31 December 2025, reporting continued strong revenue growth and a return to profitability. Financial Performance Revenue increased 53% to $8M (1H FY25: $5.27M), driven by continued execution across all three business units: • $4.4M in revenue
In the deck
Story so far
Earlier from Resonance Health
- Half Year Report & Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
- AGM Presentation
- Investor Strategy Day Presentation
- FY25 Full Year Results & FY26 Guidance Investor Presentation
Later from Resonance Health
- Half Year Results Presentation
- Receipt of R&D Tax Incentive Refund
- Profit Guidance Upgrade
- Liver Fibrosis Device Progress & FY26 Portfolio Webinar
- FY26 Full Year Results & Investor Webinar
Follow Resonance Health into a list and get an email when it puts out news.
Follow Resonance Health